TMO Quantitative Stock Analysis

Validea's guru fundamental report for Thermo Fisher Scientific (TMO) assigned the medical equipment large-cap a 66% rating using Partha Mohanram's P/B Growth Investor model, falling below the 80% threshold for typical strategy interest. While TMO passed key financial health metrics like book-to-market ratio, return on assets, and cash flow, it notably failed criteria related to advertising, capital expenditures, and R&D as a percentage of assets. This indicates that despite its growth stock classification, TMO does not strongly align with Mohanram's model for identifying companies with characteristics associated with sustained future growth.

Analysis

According to a Validea fundamental report, Thermo Fisher Scientific (TMO) receives a lukewarm rating of 66% based on Partha Mohanram's P/B Growth Investor model, a score that falls below the 80% threshold indicating strategic interest. This model is specifically designed to identify low book-to-market stocks with characteristics of sustained future growth. TMO demonstrates foundational financial health by passing criteria related to its book-to-market ratio, return on assets (ROA), and cash flow from operations relative to assets. However, the analysis reveals significant weaknesses from this model's perspective, as TMO fails on three key growth-investment metrics: advertising-to-assets, capital expenditures-to-assets, and research and development-to-assets. This suggests that while TMO appears stable based on current profitability and cash generation, its level of reinvestment into future growth drivers does not meet the standards of a model designed to separate high-potential growth stocks from their peers.

Key Decisions for Investors

• Growth-focused investors should note that TMO's profile does not align with the Mohanram model's criteria for sustained growth, primarily due to lower-than-expected investment in R&D and capital expenditures relative to its asset base.
• Investors should scrutinize TMO's capital allocation strategy to understand the rationale behind its lower intensity of spending on growth initiatives, as this is the key point of failure in this specific quantitative screen.
• While the stock passes on core financial stability metrics like ROA and cash flow, the failure on growth investment metrics suggests it may be more suitable for a 'Growth at a Reasonable Price' (GARP) portfolio rather than a pure, high-growth strategy.